Home › Companies › Syndax Pharmaceuticals, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed May 16, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 14, 2025: 5 items on Syndax Pharmaceuticals, Inc.’s Form 8-K, filed May 16, 2025: 5 passed (calculated).
Significant dissent: 1 director (29.1% against).
Notable dissent: 1 director (19.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Keith A. Katkin | 53,552,483 | -- | -- | 12,880,619 | 4,852,212 | 81% | Passed (calculated) | — |
| Elect Director: Dennis G. Podlesak | 47,082,144 | -- | -- | 19,350,958 | 4,852,212 | 71% | Passed (calculated) | — |
| Elect Director: Aleksandra Rizo, M.D., Ph.D. | 63,139,437 | -- | -- | 3,293,665 | 4,852,212 | 95% | Passed (calculated) | — |
| 2. Advisory vote on executive compensation | 62,495,031 | 3,829,672 | 108,399 | -- | 4,852,212 | 94% | Passed (calculated) | — |
| 3. Ratification of selection of independent registered public accounting firm | 71,183,107 | 71,909 | 30,298 | -- | -- | 99.9% | Passed (calculated) | — |
Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 16, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
223 asset managers disclosed a vote on at least one Syndax Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Aleksandra Rizo, M.D., Ph.D.
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Aleksandra Rizo, M.D., Ph.D.”): 63,139,437 for, 3,293,665 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 18,131,762 for, 427,120 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,901,899 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 305,130 | Withhold |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| JPMorgan | 233,378 | 0 | 0 | 0 | For |
| Goldman Sachs | 227,788 | 0 | 0 | 0 | For |
| Equitable | 129,993 | 0 | 0 | 83,950 | Mixed |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 96,967 | 0 | 0 | 8,137 | Mixed |
| Victory Capital | 103,834 | 0 | 0 | 0 | For |
| Aberdeen | 99,340 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 76,818 | 0 | 0 | 0 | For |
| Brighthouse | 61,846 | 0 | 0 | 0 | For |
| John Hancock | 60,983 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 55,820 | 0 | 0 | 0 | For |
| ProShares | 52,590 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Dennis G. Podlesak
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Dennis G. Podlesak”): 47,082,144 for, 19,350,958 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 15,031,697 for, 3,527,185 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 3,288 | 0 | 0 | 1,898,611 | Withhold |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 305,130 | Withhold |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| JPMorgan | 233,378 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 227,788 | Withhold |
| Equitable | 129,993 | 0 | 0 | 83,950 | Mixed |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 180,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 105,104 | Withhold |
| Victory Capital | 0 | 0 | 0 | 103,834 | Withhold |
| Aberdeen | 0 | 0 | 0 | 99,340 | Withhold |
| Lincoln Financial | 17,056 | 0 | 0 | 60,806 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 76,818 | Withhold |
| Brighthouse | 32,090 | 0 | 0 | 29,756 | Mixed |
| John Hancock | 0 | 0 | 0 | 60,983 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 55,820 | Withhold |
| ProShares | 0 | 0 | 0 | 52,590 | Withhold |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Keith A. Katkin
Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Keith A. Katkin”): 53,552,483 for, 12,880,619 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 17,077,965 for, 1,480,917 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,900,031 | 0 | 0 | 1,868 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 305,130 | Withhold |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| JPMorgan | 233,378 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 227,788 | Withhold |
| Equitable | 129,993 | 0 | 0 | 83,950 | Mixed |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 180,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 105,104 | Withhold |
| Victory Capital | 0 | 0 | 0 | 103,834 | Withhold |
| Aberdeen | 0 | 0 | 0 | 99,340 | Withhold |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 76,818 | Withhold |
| Brighthouse | 32,090 | 0 | 0 | 29,756 | Mixed |
| John Hancock | 0 | 0 | 0 | 60,983 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 55,820 | Withhold |
| ProShares | 0 | 0 | 0 | 52,590 | Withhold |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Prior year: 73.9% for (May 15, 2024 meeting) ▲ 20.3 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.
Syndax Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory vote on executive compensation”): 62,495,031 for, 3,829,672 against, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,901,787 | 112 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 305,130 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| JPMorgan | 233,378 | 0 | 0 | 0 | For |
| Goldman Sachs | 227,788 | 0 | 0 | 0 | For |
| Equitable | 213,943 | 0 | 0 | 0 | For |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 148,217 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 105,104 | 0 | 0 | 0 | For |
| Victory Capital | 103,834 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 99,340 | 0 | 0 | Against |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 76,818 | 0 | 0 | 0 | For |
| Brighthouse | 61,846 | 0 | 0 | 0 | For |
| John Hancock | 60,983 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 55,820 | 0 | 0 | 0 | For |
Fund voting reports, all 56 managers: 18,561,659 for, 118,257 against, 22,313 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Kynam Capital Management, LP | 7,541,277 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 4,212,270 | 0 | 0 | 0 | For |
| State Street | 3,539,681 | 26,696 | 0 | 0 | For |
| BlackRock | 3,398,945 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,024,784 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,010,667 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 1,993,799 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,890,540 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,804,360 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 1,537,587 | 0 | 0 | 0 | For |
| Point72 | 1,249,353 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,221,269 | 0 | 0 | Against |
| Aisling Capital Management LP | 1,025,000 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 955,237 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 926,424 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 925,000 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 755,304 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 751,819 | 0 | 0 | 0 | For |
| Two Sigma | 749,754 | 0 | 0 | 0 | For |
| Charles Schwab | 693,666 | 0 | 0 | 0 | For |
| Northern Trust | 647,435 | 4,549 | 0 | 0 | For |
| Saturn V Capital Management LP | 581,300 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 542,002 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 524,497 | 0 | 0 | 0 | For |
| Exome Asset Management LLC | 486,647 | 0 | 0 | 0 | For |
Institutional-manager reports, all 181 managers: 47,496,264 for, 2,106,479 against, 1,654 abstained, 292 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Majority: yes · of votes cast
Prior year: 99.6% for (May 15, 2024 meeting) ▲ 0.3 pts
Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
Syndax Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 71,183,107 for, 71,909 against, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the shares present or represented, the standard stated in the company’s proxy statement: votes for exceeded votes against plus abstentions.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Syndax Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 148,217 for, 19,775 withheld).
The 54 asset managers below reported 18,528,101 for, 1,461 against, 22,313 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,649,438 | 0 | 0 | 0 | For |
| BlackRock | 3,921,294 | 0 | 0 | 0 | For |
| Fidelity | 1,965,078 | 0 | 0 | 0 | For |
| State Street | 1,901,787 | 112 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,178,062 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,165,927 | 0 | 0 | 0 | For |
| Charles Schwab | 693,127 | 0 | 0 | 0 | For |
| Dimensional | 305,130 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 280,520 | 0 | 0 | 0 | For |
| JPMorgan | 233,378 | 0 | 0 | 0 | For |
| Goldman Sachs | 227,788 | 0 | 0 | 0 | For |
| Equitable | 213,943 | 0 | 0 | 0 | For |
| TIAA | 200,197 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 141,074 | 0 | 0 | 0 | For |
| Thornburg | 133,548 | 0 | 0 | 0 | For |
| Jackson National | 105,104 | 0 | 0 | 0 | For |
| Victory Capital | 103,834 | 0 | 0 | 0 | For |
| Aberdeen | 99,340 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,862 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 76,818 | 0 | 0 | 0 | For |
| Brighthouse | 61,846 | 0 | 0 | 0 | For |
| John Hancock | 60,983 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 55,820 | 0 | 0 | 0 | For |
| ProShares | 52,590 | 0 | 0 | 0 | For |
Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 86,047,032 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.40% |
| 2 | BlackRock | 4.56% |
| 3 | Fidelity | 2.28% |
| 4 | State Street | 2.21% |
| 5 | MUTUAL FUND SERIES TRUST | 1.37% |
| 6 | FRANKLIN STRATEGIC SERIES | 1.35% |
| 7 | Charles Schwab | 0.81% |
| 8 | Dimensional | 0.35% |
| 9 | Exchange Place Advisors Trust | 0.33% |
| 10 | JPMorgan | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Kynam Capital Management, LP | 8.76% |
| 2 | Eversept Partners, LP | 4.90% |
| 3 | State Street | 4.14% |
| 4 | BlackRock | 3.95% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.35% |
| 6 | FRANKLIN ADVISERS INC | 2.34% |
| 7 | Sofinnova Investments, Inc. | 2.32% |
| 8 | Woodline Partners LP | 2.20% |
| 9 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.10% |
| 10 | Catalio Capital Management, LP | 1.79% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Entities affiliated with BlackRock, Inc. | 8,787,650 | 10.21% | Proxy statement (DEF 14A), proxy filed April 1, 2025 |
| BlackRock | 8,542,251 | 9.93% | Form 13F, quarter ended March 31, 2025 |
| Entities affiliated with Kynam Capital Management, LP | 8,520,000 | 9.90% | Proxy statement (DEF 14A), proxy filed April 1, 2025 |
| Kynam Capital Management, LP | 8,520,000 | 9.90% | Schedule 13G, filed February 14, 2025 |
| Vanguard Group | 4,871,065 | 5.66% | Form 13F, quarter ended March 31, 2025 |
| Point72 | 4,208,700 | 4.89% | Form 13F, quarter ended March 31, 2025 |
| State Street | 3,971,732 | 4.62% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 3,921,541 | 4.56% | Form 13F, quarter ended March 31, 2025 |
| Citadel Advisors | 3,021,482 | 3.51% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 2,281,916 | 2.65% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 86,047,032 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Syndax Pharmaceuticals, Inc.'s shareholder meeting held May 14, 2025, in the 2024-2025 proxy season, 223 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,045 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 16, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Syndax Pharmaceuticals (SNDX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/syndax-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.